Nifty top losers today, July 22: Shriram Finance, Eicher Motors, Jio Financial, Adani Ports, Bajaj Auto and more
The day saw several big names from the Nifty 50 pack under pressure. Among the biggest losers of the day were well-known names such as Shriram Finance, Eicher Motors and Jio Financial Services. Let's take a closer look at the top losers of the Nifty 50, according to Trendlyne. Nifty 50 top losers on July 22 Shriram Finance closed at ₹640.9, down 2.3%
Eicher Motors closed at ₹5,441.0, down 2.1%
Jio Financial Services closed at ₹311.0, down 2.0%
Adani Ports & SEZ closed at ₹1,424.8, down 1.8%
Bajaj Auto closed at ₹8,290.0, down 1.8%
Tata Motors closed at ₹675.5, down 1.7%
Dr. Reddy's Laboratories closed at ₹1,240.0, down 1.5%
Hero MotoCorp closed at ₹4,344.0, down 1.5%
State Bank of India closed at ₹814.7, down 1.2%
IndusInd Bank closed at ₹849.0, down 1.2%
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash Adani PortsBajaj AutoEicher MotorsJio FinancialNiftyShriram Finance
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
BEML bags defence order worth Rs 293.82 crore for supply of HMV 6×6 vehicles
BEML Limited has announced that it has secured a fresh order worth approximately ₹293.82 crore from the Ministry of Defence for the supply of High Mobility Vehicles (HMV) 6X6. The disclosure was made pursuant to Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015. This new contract strengthens BEML's position as a key defence equipment supplier, highlighting its capability to deliver advanced, indigenous mobility solutions for the armed forces under the government's 'Make in India' initiative. Notably, on July 18, BEML had also announced a separate order worth ₹185.65 crore from the Ministry of Defence (E-in-C) for the supply of bulldozers. That earlier order, which was made in the normal course of business, further deepened the company's long-standing relationship with the Ministry and added to its already strong defence-focused order pipeline. While the bulldozer order is unrelated to the latest HMV contract, both reinforce BEML's critical role in supporting India's defence infrastructure through consistent and high-quality equipment deliveries. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Dr Reddy's Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up
Dr. Reddy's Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported a net profit of ₹1,417.8 crore, up 1.8% from ₹1,392 crore in the same quarter last year. Revenue for the quarter stood at ₹8,545 crore, marking a strong 11.4% year-on-year (YoY) growth compared to ₹7,672.7 crore in Q1 FY25. The company's operating performance also showed improvement, with EBITDA rising 5% YoY to ₹2,278 crore, up from ₹2,160 crore in the previous year. However, the EBITDA margin contracted to 26.7%, compared to 28.2% in Q1 FY25, indicating cost pressures or product mix changes impacting profitability. One key weak spot was in the North American market, where sales declined by 11% YoY to ₹3,410 crore, down from ₹3,846 crore. This drop may reflect pricing pressure and competitive dynamics in the generics space. In the meantime, Dr Reddy's Laboratories shares closed at ₹1,248.00 today, slightly higher than the opening price of ₹1,240.20. The stock touched an intraday high of ₹1,252.10 and a low of ₹1,231.00 during the session. Over the past year, the stock has seen a 52-week high of ₹1,421.49 and a low of ₹1,020.00. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
3 hours ago
- Business Upturn
Natco Pharma offers to acquire 35.75% stake in South Africa's Adcock Ingram for Rs 2,000 crore
NATCO Pharma is making a bold move into the South African pharmaceutical market. The company's board has approved a major strategic investment to acquire a 35.75% stake in Adcock Ingram Holdings Limited, a leading pharmaceutical company based in South Africa. This includes NATCO's earlier holding of 0.80%. The acquisition, valued at around ₹2,000 crore (approximately ZAR 4 billion), involves buying over 5 crore shares from public shareholders and Adcock's treasury. NATCO has offered ZAR 75 (around USD 4.27) per share in an all-cash deal. If accepted, NATCO will join Bidvest, which holds the remaining 64.25%, as one of the two key stakeholders in Adcock Ingram. Adcock Ingram, founded back in 1890, operates across four main verticals—Prescription, OTC, Consumer, and Hospital products. In the financial year ending June 2024, it posted revenue of ZAR 9.6 billion (about USD 536 million), with a healthy EBITDA margin of 14.6% and net profit of ZAR 814 million (USD 45 million). This deal is part of NATCO's broader push to expand its global footprint. The company has also decided to set up a new wholly owned subsidiary in South Africa—NATCO Pharma South Africa Proprietary Limited—with an investment cap of ₹2,100 crore. The new entity will act as a holding and operational base to manage its local investments and business in the region. At the same time, NATCO plans to simplify its overseas structure by liquidating Time Cap Overseas Limited, a current wholly owned subsidiary. Post-liquidation, its Brazilian arm, NatcoFarma do Brasil Ltda., will come under direct ownership of NATCO Pharma. This acquisition is expected to unlock long-term value for both companies. For Adcock, it brings in NATCO's strength in R&D, dossier filing, IP access, and reach into regulated markets. NATCO, on the other hand, gets a foothold in a growing market and a chance to synergize operations with a respected local player. The transaction is likely to close by December 2025, subject to approvals from regulators in India and South Africa. If all goes as planned, Adcock Ingram may also be delisted from the Johannesburg Stock Exchange (JSE). Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
